bearish

BeiGene Ltd

BeiGene (6160.HK/BGNE.US) 22Q3 - The Price of Being an “Outlier”

Sales of current commercialized products isn't enough for BeiGene to turn loss into profit. BeiGene is fundamentally different from any other China pharmaceutical company.Investors need to aware of it

Equity Bottom-Up
330 Views, 28 Nov 2022 09:03
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • China Healthcare Weekly (Dec.2)- VBP Correction, Sales Ability Overweigh R&D, Expectation Difference
    04 Dec 2022
  • Pre-IPO 3D Medicines (3DM HK) - Some Points Worth the Attention; Our Thoughts on Valuation
    02 Dec 2022
  • Beijing Tiantan Biological Products (600161CH)-A Good Defensive Investment Target but May Overvalued
    30 Nov 2022
  • BeiGene (6160.HK/BGNE.US) 22Q3 - The Price of Being an “Outlier”
    28 Nov 2022
  • Akeso Biopharma (9926.HK) - The Recent Business Progress, the Valuation and the Challenges
    07 Nov 2022
  • The Future Directions of A-Share After the 20th National Congress of the CPC
    03 Nov 2022
  • Innovent Biologics Inc (1801.HK) - The Concerns and the Outlook
    25 Oct 2022
  • BeiGene (6160.HK/BGNE.US) 22H1- It Is an Indisputable Fact that BeiGene Is Difficult to Make Profits
    23 Aug 2022
x